2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM: Abstract Number: 2357

Xanthine Oxidase Inhibitors for the Prevention of Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Metabolic and Crystal Arthropathies Poster II

9:00AM-11:00AM: Abstract Number: 2504

Zoster Vaccination in Rheumatoid Arthritis Patients: An Unmet Care Gap

Quality Measures and Quality of Care Poster Session

11:00AM-12:30PM: Abstract Number: 3078

ABCG2 rs2231142 predicts Poor Response to Allopurinol in Patients with Gout

ACR Plenary Session III: Discovery 2015

11:00AM-12:30PM: Abstract Number: 3077

Anakinra in Patients with Cortico-Dependent Idiopathic Recurrent Pericarditis: A Randomised Double-Blind Placebo-Controlled Withdrawal Trial

ACR Plenary Session III: Discovery 2015

11:00AM-12:30PM: Abstract Number: 3079

Efficacy and Safety of Riociguat in Patients with Pulmonary Arterial Hypertension (PAH) Associated with Connective Tissue Disease (CTD)

ACR Plenary Session III: Discovery 2015

11:00AM-12:30PM: Abstract Number: 3076

Interferon Gamma (IFNg) Is the Driving Mediator of Secondary Hemophagocytic Lymphohistiocytosis (sHLH) in TLR9-Mediated Pathogenesis in Mice and Is Correlated to Disease Parameters in Children

ACR Plenary Session III: Discovery 2015

11:00AM-12:30PM: Abstract Number: 3075

Salivary Gland FcRL4+ B-Cells Are a Potential Source of Progenitor Cells for MALT Lymphoma in Primary Sjögren’s Syndrome

ACR Plenary Session III: Discovery 2015

11:00AM-12:30PM: Abstract Number: 3074

The Shared Rheumatoid Arthritis HLA-DRB1 Susceptibility Epitope Shapes the Molecular Orientation of Citrulline and the Autoreactive T Cell Receptor Repertoire

ACR Plenary Session III: Discovery 2015

2:30PM-4:00PM: Abstract Number: 3122

A Longitudinal Analysis of Change in Lupus Nephritis in an International Inception Cohort Using a Multistate Markov Model Approach

Systemic Lupus Erythematosus - Clinical Aspects and Treatment V: Neuropsychiatric Lupus

2:30PM-4:00PM: Abstract Number: 3140

A Meta-Immunochip Analysis Suggests IL12B As a Common Susceptibility Factor for Large-Vessel Vasculitides

Vasculitis III

2:30PM-4:00PM: Abstract Number: 3091

A Randomized, Controlled Trial of Pregabalin in Adolescent Patients (12-17 years) with Fibromyalgia

Fibromyalgia: Clinical Issues

2:30PM-4:00PM: Abstract Number: 3104

Abnormal DNA Methylation in a Novel PTPN11 Enhancer Increases Destructive Potential of Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS) and Joint Inflammation

Rheumatoid Arthritis - Human Etiology and Pathogenesis III

2:30PM-4:00PM: Abstract Number: 3100

Anti-RA33 Citrullinated/Native Double-Reactive Antibodies Identify Patients with the Highest Risk of Radiographic Progression in Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects IV: Biomarkers, Disease Progression and Treatment Response

2:30PM-4:00PM: Abstract Number: 3083

Antibody Array Based Proteomic Screening of 274 Serum Markers in Systemic Lupus Erythematosus

2015 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship

2:30PM-4:00PM: Abstract Number: 3124

Associations of Circulating Cell-Free Micro-RNA with Vasculopathy and Vascular Events in SLE Patients

Systemic Lupus Erythematosus - Clinical Aspects and Treatment V: Neuropsychiatric Lupus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].